{"id":519921,"date":"2021-07-29T08:33:44","date_gmt":"2021-07-29T12:33:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"modified":"2021-07-29T08:33:44","modified_gmt":"2021-07-29T12:33:44","slug":"neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","title":{"rendered":"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., July  29, 2021  (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc.\u00a0(NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Canaccord Genuity 41<sup>st<\/sup> Annual Growth Conference on\u00a0Thursday, August 12, 2021. The Company is scheduled to present at the conference at\u00a09:30 am Eastern Time the same day via webcast.<\/p>\n<p>A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UHpXA5Ju0UTDolZL8Gyqqyo_tSGUz9aF7JrKx_wmecCczIw5lpwzp-z92xve8cJ8uSCxs86tGzUhgaovSEHwXN1Feb9jqkz1XDGfGelzizFdHlvuBpNo9zo8HdlWKIz93U5AKDGbEae3QjrkxkbFhabEwbI_dWDehhfEn7C1Sk-HneLp39Tz3P4dS8C_MSKwfeitQEFx0d7CYR-4zk6cyLk4gdEe2NFwM5fETF4FGREP1bCehdVC88xKM61pwS1CC1EsxZwxObWT8KJPHfYPUirBseqZe6Ll7x3J0S0UVs-A7Tgl-nbK9lAFfohLjcok\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>ir.neuronetics.com<\/u><\/strong><\/a>. A replay of the webcast will be archived on the website for approximately 90 days.<\/p>\n<p><strong>About\u00a0Neuronetics<\/strong><br \/>Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar\u00ae Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan\u2019s national health insurance. Additional information can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=45ezuNz-pn0JmCFm_4_-XFptPxsGNtRsiFfxPMq_iPT8G8vYZuf4fOPqGNTZNZljypmIgs8xqdYc4U0OrTZFpmZzzNHVWzqff05jTfH5QjAQmPlFbvpwOG3F1_rlNCRRdeYK4wM-AQQvf-YXIYUYP94eGAN3ldjQZg16wJafBU2m5aUdyR2AIOegxePWE4Ia2L5b-miEwMw4lIKcH8AkzNuiqiVDaCWon3XrVnlLM6ctCuzClpryy58zINumpLx3\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>www.neuronetics.com<\/u><\/strong><\/a>.<\/p>\n<p><strong>Investor Contact:<\/strong><br \/>Mike Vallie or Mark Klausner<br \/>Westwicke Partners<br \/>443-213-0499<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7XRQhbJ3Nn9JE5-uh56BZFIlxrq60clNmxTYWan21sLAOW3ziqJJeDVhPHDj_OJuYDvk-4E0H_tllcQusyOnCBOdprtY8qVKHGLmwL7sRUA=\" rel=\"nofollow noopener\" target=\"_blank\">ir@neuronetics.com<\/a><\/strong><\/p>\n<p><strong>Media Contact:<\/strong><br \/>EvolveMKD<br \/>646.517.4220<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IK1v8Z1i_ewjFoMPCqNpraj7nC9q8GER55Pq2OfzxGb-Ub5wtrGSeYf0921Nx6UY9fBtwWvPCKU6BDsVfzCV82er163VVqIXaUFl4zHM_zU=\" rel=\"nofollow noopener\" target=\"_blank\">NeuroStar@evolvemkd.com<\/a><\/strong><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/be88e51f-3ad1-42c7-94e4-ee01dd84019d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc.\u00a0(NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Canaccord Genuity 41st Annual Growth Conference on\u00a0Thursday, August 12, 2021. The Company is scheduled to present at the conference at\u00a09:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at\u00a0ir.neuronetics.com. A replay of the webcast will be archived on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519921","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc.\u00a0(NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Canaccord Genuity 41st Annual Growth Conference on\u00a0Thursday, August 12, 2021. The Company is scheduled to present at the conference at\u00a09:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at\u00a0ir.neuronetics.com. A replay of the webcast will be archived on &hellip; Continue reading &quot;Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T12:33:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference\",\"datePublished\":\"2021-07-29T12:33:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"wordCount\":303,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\",\"name\":\"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=\",\"datePublished\":\"2021-07-29T12:33:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","og_description":"MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Neuronetics, Inc.\u00a0(NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Canaccord Genuity 41st Annual Growth Conference on\u00a0Thursday, August 12, 2021. The Company is scheduled to present at the conference at\u00a09:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company\u2019s website at\u00a0ir.neuronetics.com. A replay of the webcast will be archived on &hellip; Continue reading \"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T12:33:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference","datePublished":"2021-07-29T12:33:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"},"wordCount":303,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/","name":"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=","datePublished":"2021-07-29T12:33:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODYzMCM0MzIwMTUwIzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-to-present-at-the-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519921"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519921\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}